Active — Not RecruitingNot Applicable

Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

France69 participantsStarted 2022-03-23

Plain-language summary

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years old or older * HTLV-1 infected * T lymphoproliferation induced by HTLV-1 (cohort 1) * without T lymphoproliferation induced by HTLV-1 (cohort 2) * informed and accepted the collection of data Exclusion Criteria \- Patients refusal of participation

What they're measuring

Number of survivors

Timeframe: Up to 1 year

Trial details

NCT IDNCT05237245

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-03

View on ClinicalTrials.gov More Lymphoproliferation Induced by HTLV-1 trials